Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Current Leases (2022 - 2025)

Historic Current Leases for Oncology Institute (TOI) over the last 4 years, with Q3 2025 value amounting to $7.2 million.

  • Oncology Institute's Current Leases rose 610.46% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 610.46%. This contributed to the annual value of $6.8 million for FY2024, which is 683.64% up from last year.
  • Per Oncology Institute's latest filing, its Current Leases stood at $7.2 million for Q3 2025, which was up 610.46% from $7.0 million recorded in Q2 2025.
  • Oncology Institute's Current Leases' 5-year high stood at $7.2 million during Q3 2025, with a 5-year trough of $4.3 million in Q1 2022.
  • For the 4-year period, Oncology Institute's Current Leases averaged around $6.1 million, with its median value being $6.4 million (2023).
  • Its Current Leases has fluctuated over the past 5 years, first soared by 3377.17% in 2023, then surged by 610.46% in 2025.
  • Over the past 4 years, Oncology Institute's Current Leases (Quarter) stood at $5.5 million in 2022, then increased by 15.73% to $6.4 million in 2023, then rose by 6.84% to $6.8 million in 2024, then increased by 5.34% to $7.2 million in 2025.
  • Its Current Leases was $7.2 million in Q3 2025, compared to $7.0 million in Q2 2025 and $6.8 million in Q1 2025.